

## The Impact of 12 Weeks Exercise Training on Circulating Soluble-Klotho and Pro - BNP in Coronary Artery Disease Patients

Mo Saghiv<sup>1</sup>, Goldhammer E<sup>2</sup>, Radziszewski E<sup>2</sup>, Sherve Ch<sup>1</sup>, Maor I<sup>2</sup> and Rosenschein U<sup>2</sup>

<sup>1</sup>Department of Exercise Physiology, Harold C. Miller Center, University of Mary, Bismarck, ND, USA.

<sup>2</sup>Department of Cardiology and Cardiac Rehabilitation, Bnei - Zion Medical Center, and Faculty of Medicine, Technion, Haifa, Israel.

### \*Correspondence:

Goldhammer E, Department of Cardiology and Cardiac Rehabilitation, Bnei-Zion Medical Center, and Faculty of Medicine, Technion, Haifa, Israel, E-mail: egoldh@013net.net.

Received: 27 October 2017; Accepted: 19 November 2017

**Citation:** Mo Saghiv, Goldhammer E, Radziszewski E, et al. The Impact of 12 Weeks Exercise Training on Circulating Soluble-Klotho and Pro - BNP in Coronary Artery Disease Patients. *Cardiol Vasc Res.* 2017; 1(1); 1-4.

### ABSTRACT

**Background:** Klotho protein is a membrane-based circulating protein that regulates cell metabolism, as well as the lifespan modulating activity of Fibroblast Growth Factors (FGFs). Higher plasma circulating Klotho levels reduce cardiovascular risk, suggesting Klotho has a protective role in cardiovascular diseases. Brain natriuretic peptide is a prognostic marker in coronary artery disease (CAD) patients, and in particular in CAD patients with heart failure. Aerobic exercise reduces the risk of cardiovascular events and mortality in patients with proven coronary artery disease (CAD), thus, S-Klotho serum levels were assessed in order to find out whether exercise can modulate its activity. Purpose: to assess the impact of 12 weeks exercise training program on S-Klotho and pro- BNP levels in coronary artery disease patients, and to assess possible correlation between S-Klotho and pro-BNP II.

**Methods:** S-Klotho and pro-BNP serum were assessed in 2 groups: gr. A = 41 coronary artery disease patients (CAD), age 59.6 years  $\pm$  2.2 sd, all with recent (< 45 days) aorto coronary by- pass surgery (CABG) years, myocardial infarction (MI), or percutaneous intervention (PCI) who were recruited to a 12 weeks supervised aerobic exercise program (45 min/4-5 sessions/week), and gr. B, a control group consisting of 17 CAD patients, age 61 years  $\pm$  2.4sd who continued their usual treatment and lifestyle with no active exercise intervention. Assessment was done twice, prior to exercise program and at the end of 12 weeks intervention. Blood samples were drawn from a forearm vein after overnight fasting, s-Klotho levels in the serum were analyzed using an  $\alpha$ -klotho enzyme linked immunosorbent assay Elisa kit (IBL, Immuno-Biological Laboratories Co., Japan) and the pro- BNP was measured as well by an immunoassay method using the Cobas e - 411 analyzer, Roche Diagnostics, Mannheim, Germany.

**Results:** No significant ( $p=0.27$ ) difference was found at baseline for S-Klotho levels between the two groups, 770.49pg/ml  $\pm$  202.20 sd and 727.54pg/ml  $\pm$  207.83 sd respectively, while a significant difference was found following exercise intervention, 863.39 pg/ml  $\pm$  213.66 sd in gr. A compared to 677.71pg/ml  $\pm$  167.46 sd in gr. B,  $p < 0.01$ . S-Klotho and BNP showed an inverse correlation at baseline in group A,  $r = -0.803$ ,  $P < 0.01$  and in group B,  $r = -0.850$ ,  $p < 0.01$ , with similar values post 12 weeks,  $r = -0.829$  &  $-0.834$  respectively.

**Conclusions:** Aerobic exercise may modulate S-Klotho activity, thus conferring a possible mechanism for the enhanced survival of coronary artery patients participating in an exercise based cardiac rehabilitation program.

### Keywords

Exercise, Coronary Artery, Cardiovascular disease, Rehabilitation program.

### Introduction

In 1997 the gene that seems to control aging was discovered by Kuro-o et al. in 1997 [1] and was named it Klotho. The name

derives from the Greek goddess of life who is involved in vascular disease. Klotho is one of the Greek Moirai, the goddesses of fate who controlled the ultimate destiny of man, the death. Klotho spins the thread of life, Lakheia measured the thread of life, and Atropos cut the thread of life. Kuro-o in his pioneer work identified Klotho in a mutant mouse strain that could not express Klotho gene, developed multiple disorders resembling human aging, and had a shortened life span [2]. The aging phenotypes included atherosclerosis, endothelial dysfunction, sarcopenia, skin atrophy, and impaired cognition. Overexpression of Klotho resulted in transgenic mice resulted in a significantly longer life span [3]. In an atherosclerotic mouse model, the in vivo gene delivery of Klotho protected against endothelial dysfunction [4]. Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23 [5].

Arking [6], found association between a functional variant of the Klotho gene and high density lipoprotein cholesterol, blood pressure, stroke, and longevity. Similarly, in community dwelling adults, higher plasma Klotho concentrations were independently associated with a lower likelihood of having cardiovascular disease [7]. Reduced Klotho was found to be associated with presence and severity of coronary artery disease [8], Moe S, in her editorial in *Circulation* [9] suggested that Klotho might even be considered the master regulator of cardiovascular disease. The reduction of circulating levels of Klotho is not only associated with the presence and severity of CAD, it is also an independent marker of some forms of vascular dysfunction such as arterial stiffness and endothelial dysfunction. It is related as well to the attenuation of vascular calcification as well as prevention of cardiac hypertrophy [10-12]. Exercise and exercise training has been related with increased Klotho serum levels in several works [13-15], thus conferring potentially beneficial cardiovascular effects. Brain natriuretic peptide (BNP) as well as Pro- BNP has been shown to be reduced following exercise training in CAD patients, with heart failure in particular [16-18].

Therefore, the purpose of the present study was to assess the effect of a 12 weeks exercise based cardiac rehabilitation programs in CAD patients with recent MI, PCI, and CABG on S-Klotho serum levels, and to assess possible association with BNP activity.

## Methods

Subjects - 41 CAD patients, age - 59.6 years  $\pm$  2.2 s.d., 30 males & 11 females who had a recent (<45 days) MI, PCI, or CABG were included in gr. A and underwent a supervised 12 weeks aerobic exercise based cardiac rehabilitation (45 min/4-5 sessions/week) and 17 age matched patients (age 61 years  $\pm$  2.4 s.d. 12 males & 5 females) with proven CAD (recent or old MI, previous PCI or CABG) were included in the control group, gr. B. and required to continue their usual medical treatment and their usual lifestyle habits without a supervised exercise intervention. Gr. A patients were prescribed an individually tailored exercise program according to 75%-80% of their maximal heart rate achieved in a symptom limited exercise test performed at baseline, 24 hours

prior to exercise program initiation. All patients, in both groups were in NYHA class I – II, mean left ventricular ejection fraction % (LVEF%) was 36.5  $\pm$  4.1 in gr. A, and 35  $\pm$  3.3 in gr. B (p=ns), risk factors prevalence was similar in both groups, with diabetes mellitus being more frequent in gr. A (11 patients, 26.8% vs 3 in gr. B, 17.6%), while smoking more in Gr. B (17.6% vs 14.6%).

Exclusion criteria included renal failure with creatinine levels  $\geq$  2.0 mg/dL, liver dysfunction, non-controlled hypertension, neurological or orthopedic diseases limiting patient ability to perform aerobic exercise.

Blood sampling - Peripheral venous blood samples (5 mL) were collected twice, at baseline, (in gr. A before the stress test was performed), and following 12 weeks, by an antecubital venipuncture technique into ethylenediaminetetraacetate containing tubes. Time of day for blood sampling was in the morning and was kept consistent to avoid possible diurnal variation.

## Analysis

Blood samples were centrifuged for 15 minutes at 2700 rpm, separated and frozen at  $-70^{\circ}\text{C}$  until use. S-Klotho levels in the serum were analyzed using a  $\alpha$ -klotho enzyme linked Immunosorbent assay eliza kit (IBL, Immuno- Biological Laboratories Co, Japan). The kit has been validated and widely used for the measurement of klotho levels [10-12]. The intra- and interassay coefficients of variation ranged from 2.7 to 9.8%. Pro – BNP II was measured by an immunoassay method using the Cobas e - 411 analyzer, Roche Diagnostics, Mannheim, Germany.

All subjects (both groups) underwent a symptom limited sub maximal exercise test on a treadmill utilizing the standard Bruce protocol. Rest and peak exercise heart rate (rHR & pHR), rest and peak exercise systolic and diastolic blood pressure (rSBP, pSBP, rDBP, & pDBP), as well as the metabolic equivalents (METS) were determined. A written consent form was obtained from each subject, approved by the Clinical Science Center Committee on Human Subjects.

## Statistical methods

Continuous variables are expressed as the mean  $\pm$  SD, and comparisons between groups were made using the Student's t-test for continuous variables. To achieve a normal distribution, the Klotho and Pro-BNP-II values were log transformed prior to the analysis. Single and multiple regression analysis were performed in order to find out possible relationship between S-Klotho as dependent variable and the various coronary risk factors, METS, HR, SBP, DBP, and LVEF% being independent variables. A p value of  $<0.05$  was considered to be statistically significant, and all data were statistically analyzed using the Statistix software, version 10.

## Results

Both groups did not differ in baseline characteristics (Table 1) except for diabetes incidence that was higher in the exercise intervention group (p  $<0.05$ ) and smoking status being more frequent in the control group (p  $<0.05$ ).

Variable	Gr. A	Gr. B
No. of subjects	41	17
Age (years) ± s.d.	59.6 ± 2.2	61 ± 2.4
Male/female ratio	2.7	2.4
LVEF% ± s.d.	36.5 ± 4.1	35 ± 3.3
Smoking % and no.	14.6 (6)	23.5 (4) ^^
Diabetes % and no.	26.8 (11) ± s.d. ^^	17.6 (3)
Hypertension % and no.	36.6 (15)	35.3 (6)
r-HR (bpm) ± s.d.	71 ± 3.3	69 ± 2.6
r – SBP ± s.d.	119 ± 4.5	123 ± 3.9
METS ± s.d.	6.54 ± 1.36	6.91 ± 1.61

**Table 1:** Baseline characteristics.

^^ = p<0.05 (r-HR =rest heart rate, r-SBP = rest systolic blood pressure).

Baseline Klotho levels did not differ, 770.49 pg/ml ± 202.20sd in Gr. A compared to 727.54pg/ml ± 207.83sd in Gr. B (p=ns), while baseline BNP was higher in the control group, Gr. B compared to Gr. A, 992.49 g/ml ± 503.82sd vs 823.20pg/ml ± 499.67sd and 823.20pg/ml ± 499.67sd respectively, p<0.05.

Following 12 weeks of exercise training Klotho levels increased significantly in Gr. A, to 863.39pg/ml ± 213.66sd, p<0.05, while no change was noticed in the control group (Table 2). BNP levels were significantly reduced following exercise training program, from 823.20pg.ml ± 499.67sd to 684.90pg/ml ± 349.26sd, p<0.05, while no such change was noticed in the control group (Table 2). A single regression and multiple regression analysis showed that the Klotho levels were not correlated with LVEF%, smoking status, diabetes, and hypertension (p = ns), respectively, whereas there was an inverse correlation between the Klotho levels with the Pro-BNP (P<0.01). Another single regression analysis showed that the Klotho levels continued improving in proportion to increasing METS values, which is a sensitive survival predictor in CAD. A multiple regression analysis (Table 3) reaffirmed these results.

variable	Baseline	Post exercise
Klotho – Gr. A pg/ml	770.49 ± 202.20	863.39 ± 213.66 ^^
Pro – BNP Gr. A pg/ml	823.20 ± 499.67	684.90 ± 349.26 ^^
Klotho – Gr. B pg/ml	727.54 ± 207.83	677.71 ± 167.46
Pro – BNP Gr. B pg/ml	992.49 ± 503.82 ^^	1025.5 ± 506.47

^^ = p<0.05

Explanatory variable	Regression coefficient	Standard regression coefficient	P value	95% CI	VIF
Pro-BNP	0.040	0.183	< 0.01	0.024–0.057	1.286
LVEF%	0.012	0.009	NS (0.09)	0.007–0.018	1.257
Dyslipidemia	0.201	0.004	NS	0.070–0.332	1.085
Smoking	0.180	0.009	NS (p=0.1)	0.051–0.309	1.201
Hypertension	0.014	0.007	NS (p = 0.84)	– 0.121 to 0.149	1.111

**Table 3:** Results of the multiple regression analysis of Klotho levels in all patients (=58).

## Discussion

Exercise capacity is known to be an important prognostic factor in patients with cardiovascular disease, and considered even to be a more powerful predictor of mortality among men than other established risk factors for cardiovascular disease [19-21]. Exercise training has been found in this study to have a possible modulatory effect on S-Klotho serum activity in CAD patients with a recent myocardial infarction or recent coronary artery perfusion procedure. This potentially beneficial effect has not proven in the control group that did not undergo an exercise training program. Regression analysis showed that the Klotho levels continued improving in the exercise intervention group in proportion to increasing METS values, thus, in accordance with the fact that exercise capacity is a powerful predictor of mortality in CAD patients. Furthermore, Klotho levels had a significant negative correlation with Pro-BNP II serum levels in both groups at baseline and following 12 weeks exercise program in Gr. A patients, thus, conferring an additional plausible explanation to the mechanisms aerobic exercise training improve survival and reduces cardiovascular morbidity in these patients. The study has two drawbacks, one, its small sample size, thus, not powered enough statistically, limiting conclusions, the second, derives from the information included in the informed consent. Patients enrolled to study were fully aware of the triad, S-Klotho, exercise, and longevity, thus, all were hyper motivated. In fact most of them reported additional exercise sessions at home.

## References

1. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. *Nature*. 1997; 390: 45-51.
2. Kuro-o M, Klotho. *Aging. Biochim Biophys Acta*. 2009; 1790: 1049–1058.
3. Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. *Science*. 2005; 309: 1829-1833.
4. Saitoa Y, Nakamura T, Ohyama T, et al. In Vivo klotho Gene Delivery Protects against Endothelial Dysfunction in Multiple Risk Factor Syndrome, *Biochemical and Biophysical Research Communications*. 2000; 276: 767–772.
5. Lim K, Tzong-Shi Lu, Molostvov G, et al. Vascular Klotho Deficiency Potentiates the Development of Human Artery Calcification and Mediates Resistance to Fibroblast Growth Factor 23. *Circulation*. 2002; 125: 2243-2255.
6. Arking DE, Atzmon G, Arking A. Association between a functional variant of the Klotho gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. *Circ Res*. 2005; 96: 412-418.
7. Semba RD, Cappola AR, Sun K, et al. Plasma klotho and cardiovascular disease in adults. *J Am Geriatr Soc*. 2011; 59: 1596–1601.
8. Navarro-González JF, Donate-Correa J, Muros de Fuentes M, et al. Reduced Klotho is associated with the presence and severity of coronary artery disease. *Heart*. 2014; 100: 34-40.
9. Moe SM, Klotho. A master regulator of cardiovascular

- 
- disease? *Circulation*. 2012; 125: 2181-2183.
10. Saito Y, Yamagishi T, Nakamura T, et al. Klotho protein protects against endothelial dysfunction. *Biochem Biophys Res Commun*. 1998; 248: 324–329.
  11. Kitagawa M, Sugiyama H, Morinaga H, et al. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. *PLoS One*. 2013; 8: e56695
  12. Martín-Núñez E, Donate-Correa J, Muros-de-Fuentes M, et al. Implications of Klotho in vascular health and disease. *World J Cardiol*. 2014; 6: 1262-1269.
  13. Matsubara T, Miyaki A, Akazawa N, et al. Aerobic exercise training increases plasma Klotho levels and reduces arterial stiffness in postmenopausal women. *Am J Physiol Heart Circ Physiol*. 2014; 306: 348–355.
  14. Avin KG, Coen PM, Huang W, et al. Skeletal muscle as a regulator of the longevity protein, Klotho. *Frontiers in Physiol*. 2014; 5: 189.
  15. Saghiv Mo, Goldhammer E, Sagiv M, et al. Effects of Aerobic Exercise Training on S-Klotho in Young and Elderly. *J Physiology*. 2015; 1: 1-6.
  16. Bordbar S, Babae Bigi MA, Aslani A, et al. Effect of endurance and strength exercise on release of brain natriuretic peptide, *J Cardiovasc Dis Res*. 2012; 3: 22–25.
  17. Giallauria F, De Lorenzo A, Pileggi F, et al. Reduction of N terminal-pro-brain (B-type) natriuretic peptide levels with exercise-based cardiac rehabilitation in patients with left ventricular dysfunction after myocardial infarction. *Eur J Cardiovasc Prev Rehabil*. 2006; 13: 625-632.
  18. Giallauria F, Lucci R, De Lorenzo A, et al. Favourable effects of exercise training on N-terminal pro-brain natriuretic peptide plasma levels in elderly patients after acute myocardial infarction, *Age Ageing*. 2006; 35: 601-607.
  19. Stewart RAH, Held C, Hadziosmanovic N, et al. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. *JACC*. 2017; 70; 14: 1689–700.
  20. Myers J, Prakash M, Froelicher V, et al. Exercise capacity and mortality among men referred for exercise testing. *N Engl J Med*. 2002; 346: 793-801.
  21. Hambrecht R, Walther C, Möbius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease, a randomized trial. *Circulation*. 2004; 109: 1371-1378.